Mortality in Multicenter Critical Care Trials: An Analysis of Interventions With a Significant Effect*

Objectives:We aimed to identify all treatments that affect mortality in adult critically ill patients in multicenter randomized controlled trials. We also evaluated the methodological aspects of these studies, and we surveyed clinicians’ opinion and usual practice for the selected interventions. Data Sources:MEDLINE/PubMed, Scopus, and Embase were searched. Further articles were suggested for inclusion from experts and cross-check of references. Study Selection:We selected the articles that fulfilled the following criteria: publication in a peer-reviewed journal; multicenter randomized controlled trial design; dealing with nonsurgical interventions in adult critically ill patients; and statistically significant effect in unadjusted landmark mortality. A consensus conference assessed all interventions and excluded those with lack of reproducibility, lack of generalizability, high probability of type I error, major baseline imbalances between intervention and control groups, major design flaws, contradiction by subsequent larger higher quality trials, modified intention to treat analysis, effect found only after adjustments, and lack of biological plausibility. Data Extraction:For all selected studies, we recorded the intervention and its comparator, the setting, the sample size, whether enrollment was completed or interrupted, the presence of blinding, the effect size, and the duration of follow-up. Data Synthesis:We found 15 interventions that affected mortality in 24 multicenter randomized controlled trials. Median sample size was small (199 patients) as was median centers number (10). Blinded trials enrolled significantly more patients and involved more centers. Multicenter randomized controlled trials showing harm also involved significantly more centers and more patients (p = 0.016 and p = 0.04, respectively). Five hundred fifty-five clinicians from 61 countries showed variable agreement on perceived validity of such interventions. Conclusions:We identified 15 treatments that decreased/increased mortality in critically ill patients in 24 multicenter randomized controlled trials. However, design affected trial size and larger trials were more likely to show harm. Finally, clinicians view of such trials and their translation into practice varied.

[1]  J. Tenhunen,et al.  Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. , 2012, The New England journal of medicine.

[2]  J. Vincent,et al.  Multicenter, randomized, controlled trials evaluating mortality in intensive care: Doomed to fail? , 2008, Critical care medicine.

[3]  Alan D. Lopez,et al.  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. , 2002, The New England journal of medicine.

[4]  N. Khardori.  Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis , 2012 .

[5]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[6]  Stephane Heritier,et al.  Intensive versus conventional glucose control in critically ill patients. , 2009, The New England journal of medicine.

[7]  A. Eden.  Noninvasive Positive-Pressure Ventilation for Respiratory Failure After Extubation , 2005 .

[8]  C. Hinds,et al.  Elevation of systemic oxygen delivery in the treatment of critically ill patients. , 1994, The New England journal of medicine.

[9]  N. Halpern,et al.  Critical care medicine in the United States 2000–2005: An analysis of bed numbers, occupancy rates, payer mix, and costs* , 2010, Critical care medicine.

[10]  Rinaldo Bellomo,et al.  Evidence-based medicine: Classifying the evidence from clinical trials – the need to consider other dimensions , 2006, Critical care.

[11]  Michael Holzer,et al.  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest , 2002 .

[12]  A. Anzueto,et al.  Noninvasive positive-pressure ventilation for respiratory failure after extubation. , 2004, The New England journal of medicine.

[13]  G. Perkins,et al.  Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial , 2012, The Lancet.

[14]  P. Plant,et al.  Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial , 2000, The Lancet.

[15]  R. Bellomo,et al.  Why we should be wary of single-center trials , 2009, Critical care medicine.

[16]  G. Bernard,et al.  Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial , 2008, The Lancet.

[17]  C. Carvalho,et al.  Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. , 1998, The New England journal of medicine.

[18]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[19]  Michael Bailey,et al.  Goal-directed resuscitation for patients with early septic shock. , 2014, The New England journal of medicine.

[20]  M. Condorelli,et al.  The Beneficial Effects of Antioxidant Supplementation in Enteral Feeding in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. , 2005, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[21]  A. Torres,et al.  Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. , 2003, American journal of respiratory and critical care medicine.

[22]  R. Favory,et al.  Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study , 2008, Critical care.

[23]  A. McDonald,et al.  Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial , 2010, The Lancet.

[24]  G. Guyatt,et al.  Ethical Issues in Stopping Randomized Trials Early Because of Apparent Benefit , 2007, Annals of Internal Medicine.

[25]  Arthur S Slutsky,et al.  High-frequency oscillation in early acute respiratory distress syndrome. , 2013, The New England journal of medicine.

[26]  J. Nicolás,et al.  Early noninvasive ventilation averts extubation failure in patients at risk: a randomized trial. , 2006, American journal of respiratory and critical care medicine.

[27]  J. Bakker,et al.  Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* , 2004, Critical care medicine.

[28]  M. Wise,et al.  Targeted temperature management at 33°C versus 36°C after cardiac arrest. , 2013, The New England journal of medicine.

[29]  M. Wysocki,et al.  Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. , 1995, The New England journal of medicine.

[30]  M. Goldman.  Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: A randomized controlled efficacy trial , 2000 .

[31]  M. Navasa,et al.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. , 1999, The New England journal of medicine.

[32]  S. Jaber,et al.  Prone positioning in severe acute respiratory distress syndrome. , 2013, The New England journal of medicine.

[33]  S. Nava,et al.  Non-invasive ventilation in elderly patients with acute hypercapnic respiratory failure: a randomised controlled trial. , 2011, Age and ageing.

[34]  D. Cook,et al.  A randomized trial of glutamine and antioxidants in critically ill patients. , 2013, The New England journal of medicine.

[35]  Wei,et al.  Pulmonary infection control window in treatment of severe respiratory failure of chronic obstructive pulmonary diseases: a prospective, randomized controlled, multi-centred study. , 2005, Chinese medical journal.

[36]  G. Morgan,et al.  Don't Know Responses in Environmental Surveys. , 1996 .

[37]  R. Kacmarek,et al.  A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: A randomized, controlled trial* , 2006, Critical care medicine.

[38]  P. Perel,et al.  Tranexamic acid for trauma – Authors' reply , 2010, The Lancet.

[39]  S. Aberegg,et al.  Delta inflation: a bias in the design of randomized controlled trials in critical care medicine , 2010, Critical care.

[40]  G. Van den Berghe,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 2000, The New England journal of medicine.

[41]  A. Schechter,et al.  Randomization in clinical trials of titrated therapies: Unintended consequences of using fixed treatment protocols* , 2007, Critical care medicine.

[42]  M. Quinlan.  A Randomized Trial of Protocol-based Care for Early Septic Shock , 2014 .

[43]  J. Nicolás,et al.  Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial , 2009, The Lancet.

[44]  J. Vincent.  We should abandon randomized controlled trials in the intensive care unit , 2010, Critical care medicine.